Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATE

0.00
  • Fate Therapeutics presented Phase 1 data at EULAR on FT819, an off-the-shelf anti-CD19 CAR T-cell therapy for systemic lupus erythematosus.
  • Results showed rapid, sustained clinical improvement with a favorable tolerability profile under reduced-intensity conditioning, supporting outpatient, same-day discharge use.
  • Findings also indicated durable B-cell depletion with a reset toward a healthier B-cell repertoire while preserving existing vaccine-derived immunity.
  • The readout supported bendamustine as the preferred conditioning approach for RECLAIM-LN, a planned Phase 2 potentially registrational trial in lupus nephritis.
  • Separate preclinical data presented for FT839 suggested broad elimination of disease-driving immune cells in rheumatoid arthritis samples without preconditioning, positioning a next-generation autoimmune program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040830PRIMZONEFULLFEED9731653) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.